GlaxoSmithKline (NYSE:GSK), one of the big pharma companies hit hardest by the patent cliff, is trying to pull ahead by both innovating in the laboratories and innovating its research and development process. In this video, health-care analyst Max Macaluso discusses Glaxo's R&D structure and weighs in on what he expects to see from this drugmaker in 2013.
Motley Fool Returns
Stock Advisor S&P 500
5 Years 53% 38%
17+ years 341% 95%
Stock Advisor launched in February of 2002. Returns as of 11/18/2019.Join Stock Advisor